Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NGR-TNF
- Development stage
- Phase 3
- Lead developer
- MolMed
- Modality
- Peptides, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
NGR-TNF (also known as NGR-hTNF) is a vascular targeting recombinant fusion protein consisting of human tumor necrosis factor-alpha (TNF-alpha) fused to the tumor-homing peptide CNGRC. This peptide selectively binds to aminopeptidase N (CD13), which is highly expressed on the endothelial cells of tumor neovasculature. By concentrating TNF-alpha at the tumor site, NGR-TNF induces changes in vascular permeability at low doses and direct vascular damage at higher doses, thereby improving the delivery of chemotherapy or exerting direct antitumor effects while minimizing systemic TNF toxicity. The European Organisation for Research and Treatment of Cancer (EORTC) conducted the Phase I EORTC 16041 trial to evaluate its safety and optimal dosing in patients with advanced solid tumors.
- Brand names
- Zafiride
- Other names
- NGR-TNF-alphaNGR-human TNF
02
Targets
TNFRSF1A (Tumor necrosis factor receptor superfamily member 1A)ANPEP (Aminopeptidase N)TNFR2 (Tumor necrosis factor receptor superfamily member 1B)
Beyond the preview
Go deeper on NGR-TNF.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NGR-TNF.